Literature DB >> 1542793

Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells.

S A Miles1, O Martínez-Maza, A Rezai, L Magpantay, T Kishimoto, S Nakamura, S F Radka, P S Linsley.   

Abstract

Oncostatin M, a cytokine produced by activated lymphoid cells, regulates the growth and differentiation of a number of tumor and normal cells. In contrast to its effects on normal endothelial and aortic smooth muscle cell cultures, Oncostatin M was a potent mitogen for cells derived from acquired immunodeficiency syndrome-related Kaposi's sarcoma (AIDS-KS). After exposure to Oncostatin M, AIDS-KS cells assumed a spindle morphology, had an increased ability to proliferate in soft agar, and secreted increased amounts of interleukin-6. Oncostatin M RNA and immunoreactive Oncostatin M protein were found in AIDS-KS-derived cell isolates. These results suggest that Oncostatin M may play a role in the pathogenesis of AIDS-KS.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1542793     DOI: 10.1126/science.1542793

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  49 in total

1.  Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo.

Authors:  C Langdon; C Kerr; M Hassen; T Hara; A L Arsenault; C D Richards
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  Kaposi's sarcoma and human dermal microvascular endothelial cells infected with Kaposi's sarcoma-associated herpesvirus express CCL21.

Authors:  Makoto Sugaya; Stacy Reed; Patrick P Rose; Stacy de la Motte; Camilo M Raggo; Stephen E Kurtz; Ashlee V Moses; Klaus Früh; Andrew Blauvelt
Journal:  J Dermatol Sci       Date:  2010-12-05       Impact factor: 4.563

Review 3.  Kaposi's sarcoma and its associated herpesvirus.

Authors:  Enrique A Mesri; Ethel Cesarman; Chris Boshoff
Journal:  Nat Rev Cancer       Date:  2010-10       Impact factor: 60.716

4.  Oncostatin m maintains the hematopoietic microenvironment and retains hematopoietic progenitors in the bone marrow.

Authors:  Ken-ichi Minehata; Masaki Takeuchi; Yoko Hirabayashi; Tohru Inoue; Peter J Donovan; Minoru Tanaka; Atsushi Miyajima
Journal:  Int J Hematol       Date:  2006-11       Impact factor: 2.490

5.  Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules.

Authors:  V Modur; M J Feldhaus; A S Weyrich; D L Jicha; S M Prescott; G A Zimmerman; T M McIntyre
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

6.  Oncostatin-M stimulates tyrosine protein phosphorylation in parallel with the activation of p42MAPK/ERK-2 in Kaposi's cells. Evidence that this pathway is important in Kaposi cell growth.

Authors:  M C Amaral; S Miles; G Kumar; A E Nel
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

7.  Oncostatin-M is an autocrine growth factor in Kaposi's sarcoma.

Authors:  J Cai; P S Gill; R Masood; P Chandrasoma; B Jung; R E Law; S F Radka
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

8.  Antiproliferative effect of retinoid compounds on Kaposi's sarcoma cells.

Authors:  J Corbeil; E Rapaport; D D Richman; D J Looney
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

Review 9.  Classic and Novel Adipocytokines at the Intersection of Obesity and Cancer: Diagnostic and Therapeutic Strategies.

Authors:  Nikolaos Spyrou; Konstantinos I Avgerinos; Christos S Mantzoros; Maria Dalamaga
Journal:  Curr Obes Rep       Date:  2018-12

10.  Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development.

Authors:  F Samaniego; P D Markham; R Gendelman; Y Watanabe; V Kao; K Kowalski; J A Sonnabend; A Pintus; R C Gallo; B Ensoli
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.